Leishmaniasis Treatment has improved significantly with advanced medications and topical treatment
Leishmaniasis is an infection caused
by a group of parasites. It is not infectious, however, because the bacteria
cause the disease, rather than the other way around. These parasites are called
"spirochetes" and they live in the soft tissues of the skin,
intestines, and intestinal tract. These are known as the Tinea species.
Leishmaniasis can affect any area of the body. In Japan, over 300 visceral
leishmaniases were reported. Some of the parts of the body are more commonly
affected than others, although all areas are affected at one time or another.
Some people will have a mild form of the disease, while others may have a more
severe case. People may also experience symptoms of leishmaniasis in some other
areas of their body besides the scalp.
The main symptom of this disease is
the development of dermatitis, which can result in scaly skin and irritation.
It can also include bald spots on the head and patches of redness on the skin.
Hair loss is also common for individuals who develop dermatitis associated with
leishmaniasis. Leishmaniasis treatment includes medications and some of
these medications have been approved by the FDA. They range from creams and
lotions to oral medications that can be used topically as well. Topical
treatments are the ones that you apply directly to the areas that are infected.
Oral medications can also be used orally, although they must be taken orally
every day or other specified times to achieve the appropriate results.
The medications used for
leishmaniasis treatment do not usually treat all of the symptoms. There are
some cases where the symptoms get better without the use of medications. In
most cases though, a licensed medical professional should be consulted before
the treatment is started. This is to make sure that there are no other medical
conditions that would make the treatment ineffective. In September 2020,
Ajinomoto Bio-Pharma Services partnered with Drugs for Neglected Disease
Initiative (DNDi) to Develop Critical Immunomodulators for cutaneous
leishmaniasis therapeutic.
Comments
Post a Comment